Abstract
Ultrasound neuromodulation is a potential alternative therapy for suppressing epileptic discharges. Recently, several human clinical trials have reported promising results from repeated focused ultrasound (FUS) treatments for temporal lobe epilepsy. In this Viewpoint, we highlight the valuable guidance of preclinical validation methods for choosing the optimal FUS parameters, thus ensuring consistency with the outcomes of clinical trials and leading human trials to the safest and most effective approaches.
| Original language | English |
|---|---|
| Pages (from-to) | 1728-1731 |
| Number of pages | 4 |
| Journal | ACS Chemical Neuroscience |
| Volume | 15 |
| Issue number | 9 |
| DOIs | |
| State | Published - 01 05 2024 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2024 The Authors. Published by American Chemical Society.
Keywords
- clinical trial
- epilepsy
- Focused ultrasound
- kainic acid model
- neuromodulation
- translation
- Ultrasonic Therapy/methods
- Animals
- Humans
- Epilepsy/therapy
- Epilepsy, Temporal Lobe/therapy
- Disease Models, Animal